GRIGUOLO, GAIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.668
EU - Europa 1.100
AS - Asia 762
SA - Sud America 38
AF - Africa 24
OC - Oceania 2
Totale 5.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.654
SG - Singapore 415
DE - Germania 345
IT - Italia 318
CN - Cina 243
FI - Finlandia 209
SE - Svezia 53
HK - Hong Kong 50
RU - Federazione Russa 40
GB - Regno Unito 38
BR - Brasile 37
FR - Francia 30
IN - India 26
NL - Olanda 18
CI - Costa d'Avorio 13
CA - Canada 11
CZ - Repubblica Ceca 10
IE - Irlanda 8
AT - Austria 7
PH - Filippine 7
EG - Egitto 6
ES - Italia 6
MK - Macedonia 5
BE - Belgio 4
JP - Giappone 3
UA - Ucraina 3
AU - Australia 2
IL - Israele 2
IR - Iran 2
KR - Corea 2
MX - Messico 2
TR - Turchia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CH - Svizzera 1
DK - Danimarca 1
HR - Croazia 1
ID - Indonesia 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
MA - Marocco 1
MY - Malesia 1
OM - Oman 1
PK - Pakistan 1
RS - Serbia 1
SC - Seychelles 1
TN - Tunisia 1
VN - Vietnam 1
Totale 5.594
Salva come PNG Salva come JPEG
Città #
Fairfield 574
Ashburn 513
Chandler 384
Woodbridge 275
Munich 272
Houston 223
Singapore 218
Cambridge 213
Seattle 185
Helsinki 181
Ann Arbor 175
Wilmington 170
Boardman 98
Padova 93
San Diego 73
Santa Clara 54
Medford 52
Princeton 52
Beijing 49
Des Moines 41
Hong Kong 36
Roxbury 30
Rome 22
London 21
Milan 20
New York 18
Pune 17
Falls Church 16
Nanjing 16
Abidjan 13
Jyväskylä 13
Falkenstein 11
Jinan 11
Nuremberg 11
Zhengzhou 11
Dallas 10
Ottawa 10
Codogno 9
Selvazzano Dentro 9
Shenyang 9
Dublin 8
Guangzhou 8
Olomouc 8
Turin 8
Villafranca Padovana 8
Shanghai 7
Washington 7
Lappeenranta 6
Los Angeles 6
Nanchang 6
Amsterdam 5
Changsha 5
Council Bluffs 5
Menouf 5
Skopje 5
Tianjin 5
Barcelona 4
Bologna 4
Brussels 4
Capo d'Orlando 4
Chiswick 4
Naples 4
Norwalk 4
Ogden 4
Paris 4
Redwood City 4
São Paulo 4
Verona 4
Haikou 3
Hamburg 3
Kunming 3
Morgano 3
Springfield 3
Taizhou 3
Venice 3
Vienna 3
Zola Predosa 3
Acerra 2
Ancona 2
Avezzano 2
Bergamo 2
Bursa 2
Carapicuíba 2
Caserta 2
Clermont-Ferrand 2
Fisciano 2
Florence 2
Hangzhou 2
Hebei 2
Hefei 2
Hounslow 2
Jiaxing 2
Kharkiv 2
Kilburn 2
Lanzhou 2
Legnaro 2
Mabalacat 2
Melbourne 2
Modena 2
Ningbo 2
Totale 4.431
Salva come PNG Salva come JPEG
Nome #
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors 300
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 269
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 218
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 193
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 158
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 150
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 142
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 137
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 134
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 133
Immune characterization of breast cancer metastases: Prognostic implications 131
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 129
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 123
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 121
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 113
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. 111
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 110
Olaparib for the treatment of breast cancer 105
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 105
Fat grafting for breast cancer patients: From basic science to clinical studies 101
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 101
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 100
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 93
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 83
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 81
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 80
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 80
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 79
Evolution of HER2-low expression from primary to recurrent breast cancer 76
A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis 75
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 73
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 71
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 71
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 70
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 69
Erbb2 mrna expression and response to ado-trastuzumab emtansine (T-dm1) in her2-positive breast cancer 67
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 60
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 60
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 59
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 56
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 55
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 54
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade 50
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 49
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials 48
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 48
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 48
Olaparib for advanced breast cancer 45
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 44
Use of electronic administrative databases to measure quality indicators of breast cancer care: Experience of five regional oncology networks in Italy 43
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy 43
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 42
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 39
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 39
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 38
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 37
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 37
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 36
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer 36
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 32
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 32
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 30
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort 30
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 28
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 28
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 27
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 24
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 24
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 24
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 21
A systematic review of contemporary phase I trials in patients with lymphoma 18
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases 16
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 15
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 15
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 15
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 15
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 13
BET inhibitors as potential anticancer agents 12
The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy 11
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 11
Totale 5.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.412
article - articoli 26.412
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.824
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020339 0 0 0 0 0 0 0 0 110 112 52 65
2020/2021829 28 85 32 51 40 137 35 57 97 142 96 29
2021/2022850 50 62 83 46 103 81 75 49 46 38 54 163
2022/2023742 122 93 40 106 76 80 26 47 93 10 41 8
2023/2024811 44 60 55 43 44 75 50 255 15 41 56 73
2024/20251.504 7 164 85 90 196 151 250 291 270 0 0 0
Totale 5.759